Genprex To Present at Biotech Showcase 2017
December 19, 2016
AUSTIN, TX, December 19, 2016 – Genprex, Inc. a biopharmaceutical company focused on the development of revolutionary immunogene therapy treatments, today announced that management will be presenting at Biotech Showcase 2017 to be held January 9-11, 2017 in San Francisco, concurrently with the J.P. Morgan Healthcare Conference, one of largest healthcare focused investor conferences in the U.S.
Rodney Varner, Chief Executive Officer, and Dr. Julien Pham, Chief Operating Officer, are scheduled to present on Monday, January 9, 2017 at 8:45 AM PT.
Genprex is a privately held, clinical-stage biopharmaceutical company focusing on developing breakthrough immunogene therapies with their lead product Oncoprex®. Oncoprex® is currently in a Phase II clinical trial for the treatment of stage IV non-small cell lung cancer in combination with Tarceva® (erlotinib)1. The company was founded in 2009 and is headquartered in Austin, Texas. For more information, please visit www.genprex.com or www.facebook.com/genprexinc.
About Oncoprex® and Lung Cancer
Lung cancer is the second most common cancer in the U.S. but the leading cause of cancer death. There are approximately 225,000 new lung cancer cases in the U.S. per year and 1.8 million worldwide. The 5-year survival rate of stage IV non-small cell lung cancer (NSCLC) is less than 1%, and treatment options beyond chemotherapy are lacking. Approved NSCLC targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. Oncoprex® is designed to provide a targeted treatment option suitable for a majority of NSCLC patients. Oncoprex® is currently being tested as a combination treatment for EGFR-negative NSCLC patients, a population that represents 85% of all NSCLC patients.
Research has shown that over 80% of all cancer cells lack a tumor suppressor gene called TUSC2 (formerly FUS1), which has shown in-vivo to affect cell proliferation and programmed cell death. Oncoprex® is an optimized TUSC2 gene encapsulated in fatty, positively charged nanovesicles, which are able to specifically target cancer cells and insert wild-type TUSC2 into cellular DNA, effectively inducing cell death. The TUSC2 gene has also been shown in previous scientific studies to be absent in small cell lung cancer, bone and soft tissue sarcoma, and breast cancer. Genprex works with world-class institutions and collaborators to in-license and develop further drug candidates. The company controls a portfolio of 30 issued and 6 pending patents covering tumor suppressors, therapeutics, diagnostics, nanovesicle delivery systems, and manufacturing processes.
Genprex is currently conducting a Phase II clinical trial of its Oncoprex® TUSC2 therapy in combination with Tarceva® in non-small cell lung cancer at an academic cancer research center in Houston, Texas.
Genprex’s mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. Our revolutionary clinical-stage products are designed to work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers.
1 Tarceva® is a registered trademark of the Roche Group, including Genentech, and OSI Pharmaceuticals.